Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Gilead Sciences (GILD) ended the recent trading session at $146.23, demonstrating a +2.06% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.51%. At the same time, the Dow added 0.53%, and the tech-heavy Nasdaq lost 1.51%. The HIV and hepatitis C drugmaker's stock has climbed by 18.06% in the past month, exceeding the Medical sector's gain of 3.1% and the S&P 500's gain of 0.93%.Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company plans to announce its earnings on February 10, 2026. The company's upcoming EPS is projected at $1.83, signifying a 3.68% drop compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $7.57 billion, indicating a 0.07% upward movement from the same quarter last year. For the full year, the Zacks Consensus Estimates project earnings of $8.13 per share and a revenue of $29.1 billion, demonstrating changes of +75.97% and 0%, respectively, from the preceding year. Any recent changes to analyst estimates for Gilead Sciences should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.33% upward. Gilead Sciences is currently a Zacks Rank #3 (Hold). In terms of valuation, Gilead Sciences is presently being traded at a Forward P/E ratio of 16.67. This signifies a discount in comparison to the average Forward P/E of 19.6 for its industry. It's also important to note that GILD currently trades at a PEG ratio of 0.76. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.48. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks